Business Summary
- Service: discovery, identification and selection of new therapeutic targets in oncology;
- Biotech: development of a portfolio of therapeutic and diagnostic projects alone or through partnerships;
- Artificial Intelligence: development of a platform for selecting new therapeutic targets in oncology.
60.3% of sales are abroad.
Number of employees: 236
Managers
Managers | Title | Age | Since |
---|---|---|---|
Fabrice Viviani
CEO | Chief Executive Officer | - | - |
Arnaud Lafforgue
DFI | Director of Finance/CFO | - | 17-12-31 |
Stéphane Gerart
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Jan Hoflack
CTO | Chief Tech/Sci/R&D Officer | 63 | 08-12-31 |
Karine Lignel
BRD | Director/Board Member | 55 | 08-05-13 |
General Counsel | - | 21-04-30 | |
Thierry Billoué
HRO | Human Resources Officer | - | 17-01-31 |
62 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kamel Besseghir
BRD | Director/Board Member | 75 | 14-02-02 |
62 | - | ||
Karine Lignel
BRD | Director/Board Member | 55 | 08-05-13 |
Fabrice Viviani
CEO | Chief Executive Officer | - | - |
Aline Aubertin
BRD | Director/Board Member | - | 21-06-23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 6,848,412 | 730,880 ( 10.67 %) | 0 | 10.67 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Pharmaceuticals: Major
|
Sector
1st Jan change | Capi. | |
---|---|---|
-1.78% | 41.36B | |
+44.81% | 41.3B | |
+4.01% | 39.61B | |
-15.14% | 25.62B | |
+3.16% | 24.09B | |
-24.08% | 18.38B | |
-2.67% | 11.82B | |
+24.76% | 11.85B | |
+7.01% | 11.07B |